Nephrol Dial Transplant (2000) 15: 611-618
© 2000 European Renal Association-European Dialysis and Transplant Association
Wegener's granulomatosis: clinical course in 108 patients with renal involvement
Department of Medicine, University Hospital of Trondheim, The Norwegian Kidney Register, 1 Institute of Medicine and 2 Department of Pathology, Haukeland University Hospital, Bergen, and 3 Department of Community Medicine and General Practice, Norwegian University of Science and Technology, Trondheim, Norway
Background. The aim of this study was to evaluate the clinical course of patients with Wegener's granulomatosis and renal involvement, with special reference to relapse rate, renal and patient survival and morbidity from serious infections.
Methods. A retrospective analysis was carried out of 108 patients presenting with Wegener's granulomatosis and active renal disease in eight hospitals in Norway between 1988 and 1998. Multivariate analysis was used to investigate whether selected variables predicted relapse, renal and patient survival and serious infections.
Results. Median follow-up was 41.5 months. Twenty-two patients (20.4%) were admitted with a need for dialysis. Complete remission was obtained in 81.5% after a median of 4 months, and 54.7% relapsed after a median of 22.5 months. Two- and five-year renal survival was 86 and 75%, respectively, and 22.8% developed end-stage renal disease (ESRD). Two- and five-year patient survival was 88 and 74%, respectively, and the cumulative mortality was 3.8 times higher than expected. The relative risk of relapse increased with the use of intravenous pulse cyclophosphamide compared with daily oral cyclophosphamide. Initial renal function predicted renal survival, and low serum albumin and high age at treatment start increased the mortality risk. Thirty one per cent of the patients were hospitalized for serious infections during follow-up. Old age increased the risk of having an infection.
Conclusions. The current treatment of Wegener's granulomatosis does not prevent relapse, development of ESRD and serious treatment-induced infections in a considerable fraction of the patients. Alternative strategies for the management of this disease will be an important objective for further studies.
Keywords: infection; relapse; remission; renal failure; survival; Wegener's granulomatosis
Correspondence and offprint requests to: Dr Knut Aasarød, Department of Medicine, University Hospital of Trondheim, Olav Kyrres gate 17, N-7006 Trondheim, Norway.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  C Charlier, C Henegar, O Launay, C Pagnoux, A Berezne, B Bienvenu, P Cohen, L Mouthon, and L Guillevin Risk factors for major infections in Wegener granulomatosis: analysis of 113 patients Ann Rheum Dis, May 1, 2009; 68(5): 658 - 663. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C Mukhtyar, O Flossmann, B Hellmich, P Bacon, M Cid, J W Cohen-Tervaert, W L Gross, L Guillevin, D Jayne, A Mahr, et al. Outcomes from studies of antineutrophil cytoplasm antibody associated vasculitis: a systematic review by the European League Against Rheumatism systemic vasculitis task force Ann Rheum Dis, July 1, 2008; 67(7): 1004 - 1010. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O. Bakoush, M. Segelmark, O. Torffvit, S. Ohlsson, and J. Tencer Urine IgM excretion predicts outcome in ANCA-associated renal vasculitis Nephrol. Dial. Transplant., May 1, 2006; 21(5): 1263 - 1269. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S N Paul, S R Sangle, A N Bennett, M El-Hachmi, R Hangartner, G R Hughes, and D P D'Cruz Vasculitis, antiphospholipid antibodies, and renal artery stenosis Ann Rheum Dis, December 1, 2005; 64(12): 1800 - 1802. [Full Text] [PDF]
|
|
|
|
 |
|
 S K Frankel, G P Cosgrove, and K K Brown Small vessel vasculitis of the lung Chronic Respiratory Disease, April 1, 2005; 2(2): 75 - 84. [Abstract] [PDF]
|
|
|
|
 |
|
 S.E. Lane, R.A. Watts, L. Shepstone, and D.G.I. Scott Primary systemic vasculitis: clinical features and mortality QJM, February 1, 2005; 98(2): 97 - 111. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Weidner, S. Geuss, S. Hafezi-Rachti, A. Wonka, and H. D. Rupprecht ANCA-associated vasculitis with renal involvement: an outcome analysis Nephrol. Dial. Transplant., June 1, 2004; 19(6): 1403 - 1411. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M.A. Little, L. Nazar, and K. Farrington Polymyalgia rheumatica preceding small-vessel vasculitis: changed spots or misdiagnosis? QJM, May 1, 2004; 97(5): 289 - 292. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. A. Little, L. Nazar, and K. Farrington Outcome in glomerulonephritis due to systemic small vessel vasculitis: effect of functional status and non-vasculitic co-morbidity Nephrol. Dial. Transplant., February 1, 2004; 19(2): 356 - 364. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. W. A. Westman, D. Selga, P.-E. Isberg, A. Bladstrom, and H. Olsson High Proteinase 3-Anti-Neutrophil Cytoplasmic Antibody (ANCA) Level Measured by the Capture Enzyme-Linked Immunosorbent Assay Method Is Associated with Decreased Patient Survival in ANCA-Associated Vasculitis with Renal Involvement J. Am. Soc. Nephrol., November 1, 2003; 14(11): 2926 - 2933. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. P. Collins, M. I. Periquet, J. R. Mendell, Z. Sahenk, H. N. Nagaraja, and J. T. Kissel Nonsystemic vasculitic neuropathy: Insights from a clinical cohort Neurology, September 9, 2003; 61(5): 623 - 630. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. P. Collins, M. I. Periquet, K. de Groot, and E. Reinhold-Keller Prevalence of Vasculitic Neuropathy in Wegener Granulomatosis Arch Neurol, August 1, 2002; 59(8): 1333 - 1334. [Full Text] [PDF]
|
|
|
|
 |
|
 W. Koldingsnes and H. Nossent Predictors of survival and organ damage in Wegener's granulomatosis Rheumatology, May 1, 2002; 41(5): 572 - 581. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Aasarod, L. Bostad, J. Hammerstrom, S. Jorstad, and B. M. Iversen Renal histopathology and clinical course in 94 patients with Wegener's granulomatosis Nephrol. Dial. Transplant., May 1, 2001; 16(5): 953 - 960. [Abstract] [Full Text] [PDF]
|
|